Beryl Drugs Limited (BOM:524606)
India · Delayed Price · Currency is INR 22.90
-0.60 (-2.55%)
At close: Jun 17, 2026
Beryl Drugs Revenue
In the fiscal year ending March 31, 2026, Beryl Drugs had annual revenue of 188.20M INR, down -11.00%. Beryl Drugs had revenue of 51.29M in the quarter ending March 31, 2026, with 29.08% growth.
Revenue
188.20M
Revenue Growth
-11.00%
P/S Ratio
0.62
Revenue / Employee
n/a
Employees
n/a
Market Cap
116.14M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 188.20M | -23.26M | -11.00% |
| Mar 31, 2025 | 211.46M | -55.83M | -20.89% |
| Mar 31, 2024 | 267.30M | -1.41M | -0.53% |
| Mar 31, 2023 | 268.71M | 122.67M | 84.00% |
| Mar 31, 2022 | 146.04M | 5.11M | 3.62% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Add-Shop E-Retail | 1.55B |
| Vivanza Biosciences | 1.16B |
| Unjha Formulations | 157.49M |
| Zenith Healthcare | 105.22M |
| Norris Medicines | 81.32M |
| Desh Rakshak Aushdhalaya | 71.04M |
| Colinz Laboratories | 61.36M |
| Ganga Pharmaceuticals | 28.28M |